Recent developments of interest in cardiovascular medicine
In the first policy statement on compensation among cardiologists, the American College of Cardiology called for more equity. Among the recommendations: healthcare facilities should not even ask salary history and not focus on negotiating skills or other personal criteria that can perpetuate inequity.
An expert consensus decision pathway from the ACC for heart failure hospitalization now suggests starting sacubitril/valsartan (Entresto) before discharge -- as long as patients can afford to stay on it afterward. (The Pharma Letter)
CAR-T immunotherapy techniques developed for cancer treatment may also help tackle fibrosis that contributes to heart failure, according to a proof-of-concept mouse study. (New York Times)
The American Society of Nuclear Cardiology and other nuclear medicine and cardiology societies released a consensus statement on best practices for imaging and diagnosing cardiac amyloidosis. (Cardiovascular Business)
An antisense drug being developed to treat transthyretin amyloidosis cut levels of that TTR protein by 86% to 94% with no serious adverse events in a phase I trial, so a phase III program is planned to start later this year, Akcea Therapeutics announced.
Apple announced it will study the link between heart rate and physical activity tracking by its Watch and hospitalizations, falls, heart health, and quality of life. (MobiHealthNews)
The gap between U.S. counties with the worst CV mortality rates
(clustered "from southeastern Oklahoma along the Mississippi River Valley to eastern Kentucky") and those with the fewest CV deaths shrank over time but still represents about a twofold difference in risk. (JAMA
About half of med students have hypertension at one university in Tennessee. (Cardiovascular Business)
The Carillon mitral repair device reduced functional mitral regurgitation and left ventricular volume in heart failure patients in a sham-controlled study in JACC: Heart Failure. (MassDevice)
A wireless cardiac resynchronization therapy system, the EBR Systems' Wise device, gained breakthrough therapy device designation from the FDA. (MassDevice)
The Virtue sirolimus-eluting balloon got breakthrough device designation for below-the-knee peripheral arterial stenosis, Orchestra BioMed announced.
Paclitaxel-coated stent mortality risk in peripheral artery disease? Not here, a retrospective Japanese study reported in the Journal of Endovascular Therapy.
Read the original article on Medpage Today: Salary Policy Shakeup; CAR-T for HF; Apple Watch Tackling Hospitalizations?